Physician profile
John Delmonte
NPI 1043427586
$2,954.19
in general payments reported to CMS, 2019-2025
45 companies · $677 in 2025
The $677 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $619 · 2020: $366 · 2021: $301 · 2022: $291 · 2023: $312 · 2024: $388 · 2025: $677.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,324 · Education: $53.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,323.59 |
| Education | $53.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $221.07 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $196.66 | 2020-2025 | Ninlaro, Iclusig |
| E.R. Squibb & Sons, L.L.C. | $189.76 | 2019-2025 | Opdivo |
| Genentech USA, INC. | $175.46 | 2019-2025 | Polivy, Venclexta, Itovebi |
| Novartis Pharmaceuticals Corporation | $167.72 | 2019-2025 | |
| Exelixis INC. | $144.73 | 2019-2025 | Cabometyx |
| Pfizer INC. | $136.01 | 2019-2025 | |
| Glaxosmithkline, LLC. | $125.55 | 2021-2025 | Jemperli, Ojjaara |
| Janssen Biotech, INC. | $116.76 | 2019-2025 | Rybrevant, Darzalex |
| Celgene Corporation | $114.57 | 2019-2022 | |
| Daiichi Sankyo INC. | $88.67 | 2022-2023 | Enhertu |
| Incyte Corporation | $83.30 | 2019-2025 | Jakafi |
| Astrazeneca Pharmaceuticals Lp | $82.35 | 2019-2022 | |
| Ipsen Biopharmaceuticals, INC | $76.51 | 2022-2025 | Onivyde, Tazverik |
| Amgen INC. | $67.21 | 2019-2020 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Delmonte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.